目的 探讨盐酸小檗碱片联合柳氮磺吡啶肠溶片治疗溃疡性结肠炎的临床疗效。方法 选取2019年2月-2020年2月在漯河市中医院诊治的溃疡性结肠炎患者94例，根据就诊顺序分为对照组（47例）和治疗组（47例）。对照组口服柳氮磺吡啶肠溶片，初始剂量为1 g/次，若无不适增至2 g/次，3次/d，待症状缓解后减至1 g/次，2次/d。治疗组在对照组的基础上口服盐酸小檗碱片，0.3 g/次，3次/d。两组患者经3个月治疗。观察两组患者临床疗效，同时比较治疗前后两组患者临床症状改善时间，DAI、ESCA、IBDQ和SF-36评分，血清白细胞介素-17（IL-17）、IL-23、低氧诱导因子-1α（HIF-1α）、环氧化酶-2（COX-2）、基质金属蛋白酶-1（MMP-1）和β-内啡肽（β-EP）水平，及二胺氧化酶（DAO）和D乳酸（D-LA）水平。结果 治疗后，对照组临床有效率为80.85%，显著低于治疗组的97.87%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组患者症状改善时间均明显早于对照组（P<0.05）。治疗后，两组患者DAI评分均显著降低（P<0.05），而ESCA评分、IBDQ评分和SF-36评分均显著升高（P<0.05），且治疗组这些评分项目明显好于对照组（P<0.05）。治疗后，两组患者IL-17、IL-23、HIF-1α、COX-2、MMP-1、β-EP、DAO、D-LA水平均明显降低（P<0.05），且治疗组患者明显低于对照组（P<0.05）。结论 盐酸小檗碱片联合柳氮磺吡啶肠溶片治疗溃疡性结肠炎可显著改善临床症状，降低炎症反应，促进肠道黏膜屏障功能改善，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Berberine Hydrochloride Tablets combined with sulfasalazine in treatment of ulcerative colitis. Methods Patients (94 cases) with ulcerative colitis in Luohe Hospital of traditional Chinese medicine from February 2019 to February 2020 were divided into control (47 cases) and treatment (47 cases) groups bases on visiting sequence. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, the initial dose was 1 g/time, if there was no discomfort, the dose was increased to 2 g/time, three times daily, and reduced the dose to 1 g/time after symptom relief, twice daily. Patients in the treatment group were po administered with Berberine Hydrochloride Tablets on the basis of the control group, 0.3 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms, the scores of DAI, ESCA, IBDQ and SF-36, the serum levels of IL-17, IL-23, HIF-1α, COX-2, MMP-1 and β-EP, and the levels of DAO and D-LA in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.85%, which was significantly lower than 97.87% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the improvement time of clinical symptoms in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, the DAI scores in two groups were significantly decreased (P<0.05), but the ESCA, IBDQ and SF-36 scores were significantly increased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the levels of IL-17, IL-23, HIF-1α, COX-2, MMP-1, β-EP, DAO and D-LA in two groups were significantly decreased (P<0.05), and these indexes in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Berberine Hydrochloride Tablets combined with Sulfasalazine Enteric-coated Tablets in treatment of ulcerative colitis can significantly improve the clinical symptoms, reduce the inflammatory reaction, promote the improvement of intestinal mucosal barrier function, which has a certain clinical application value.

R975

河南省医学科技攻关计划项目（201503236）